Oral methotrexate therapy for multiple superficial bladder carcinomata.
Patients with frequently recurring multiple class T1 bladder carcinomata have been treated with methotrexate (MTX) given as 50 mg in syrup every week. In 16 of 17 patients the frequency and number of tumor recurrences have been reduced. Measurement of MTX levels in the urine confirms that this dose of drug yields concentrations that are thought to be cytotoxic for at least 24 hours.
D000284:Administration, Oral; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage* / Q000652:urine; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000652:urine
D008727:Methotrexate